Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin gel for pediatric neurogenic bladder
NCT01192568Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2011
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of oxybutynin in neurogenic bladder, sponsored by AbbVie Inc.. Started May 2011; status: completed.
02
Drugs
oxybutynin
03
Conditions
neurogenic bladder
Beyond the preview
Go deeper on NCT01192568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01192568.